Michelle Obama has left a very important legacy in the United States, especially in the health sector with medical care and ...
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...
Robert F. Kennedy Jr., the nominee to lead the Department of Health and Human Services, made disputed claims before the ...
The FDA says new labels will make it easier to spot harmful ingredients. A UVA nutritionist suggests taking a holistic ...
Stacker on MSN2d
Diabetes and other chronic conditions are becoming common. Here's how public health efforts can help bring rates down.Dialysis Centers used data from the Centers for Disease Control and Prevention to examine the prevalence of chronic diseases ...
Intense backlash prompted the reinstatement of some online resources. But guidelines for safe contraception and information ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales of ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Rep. Chip Roy (R-TX) issued a diagnosis for America’s broken health care system, and the congressman says the problem isn’t what people think.
More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback